DPTX3186 in Wnt Pathway Activated Solid Tumors

Dewpoint Therapeutics

Status and phase

Enrolling

Phase 1

Conditions

Solid Tumors

Treatments

Drug: DPTX3186

Study type

Interventional

Funder types

Industry

Identifiers

NCT07312903

DPTX3186-101

Details and patient eligibility

About

This is a first-in human clinical study of DPTX3186 in subjects with Wnt-pathway activated solid tumors where no other treatments exist. The study will evaluate safety, pharmacokinetics, and initial activity of DPTX3186, as well as explore pharmacodynamic parameters to identify potential biomarkers of efficacy

Enrollment

40 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Histologically or cytologically confirmed solid tumor and tumor types known to be Wnt-pathway activated (such as colorectal cancer, gastric cancer, lung cancer, and triple negative breast cancer) and no other approved treatment options available.
At least one measurable target lesion as defined by RECIST v1.1 on CT, PET/CT, or MRI.
ECOG performance status of 0 or 1.
Physiological conditions that may prevent absorption of an oral medication including but not limited to colostomy and ileostomy.
Age ≥18 years (or ≥ age of majority per local regulation)
Life expectancy ≥3 months
Willing and able to comply with protocol requirements

Exclusion criteria

Symptomatic or uncontrolled brain metastasis requiring concurrent treatment,
Another known malignancy that is progressing or requires active treatment within the last 2 years (except basal cell carcinoma, in situ cervical cancer, etc.).
Inadequate organ function
Known hypersensitivity to study drug or excipients